Wednesday, March 9, 2011

ARYx: FDA decision delay leads to winding down of operations

ARYx Therapeutics Inc. said Wednesday that because of a longer than expected delay in a drug decision from the Food and Drug Administration, it will begin winding down operations.
Fremont-based ARYx (NASDAQ:ARYX) said the FDA doesn't expect to make a decision until July about naronapride, the company's product candidate for the treatment of various gastrointestinal disorders.

No comments:

Post a Comment